Investigation of replication kinetics and cell killing capacity of the oncolytic adenovirus XVir-N-31 in conjunction with targeted therapy
Year: 2024
Type: dissertation
Abstract: This study explores how small molecule inhibitors enhance the oncolytic adenovirus XVir-N-31 for treating bladder cancer. PARP inhibition boosts cancer cell killing without affecting viral replication, while BET inhibitors (BETi) accelerate viral gene expression and tumor cell lysis. BRD4, YB-1, and P300 are crucial for this effect, with BETi modifying E1A protein interactions in a wildtype similar manner. Overcoming BETi resistance, this therapy shows promise for clinical application.
Authors: Klein, Florian Gerhard, Holm, Per Sonne, Technische Universität München
Institution: Technical University of Munich
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W6987778381
